Vol. I · No. 1 · Taipei EditionThursday, 14 May 2026 · 2026-W20Last ingest 3d ago · 4/4 feeds

Agency Intel / TW

“Truth · Timing · Tradecraft” — the WPP Media Taiwan review-readiness desk
Dashboard · Roster · MNC Pharma · Eli Lilly Taiwan
№ 101 · The Eli Lilly Taiwan dossier

Eli Lilly Taiwan

台灣禮來股份有限公司
Parent: Eli Lilly and Company (NYSE: LLY)
Readiness
95
Held
Capped at 95. High confidence — AOR sourced within 3y.
Workspace · saved locally in your browser
Pipeline status
Your notes · Eli Lilly Taiwan
Saves on blur. Stored in your browser only — not synced.

Eli Lilly Taiwan (台灣禮來) is mid-tier MNC pharma in Taiwan (top 8-10 by Rx revenue) but with disproportionate strategic momentum globally — Lilly is the WORLD'S MOST VALUABLE PHARMA COMPANY by market cap (>$700B at peak 2024) driven by GLP-1 / tirzepatide platform (Mounjaro / Zepbound). Taiwan portfolio is DOMINANT in diabetes (Trulicity established, Mounjaro launching), expanding in oncology (Verzenio breast cancer), immunology (Taltz vs Cosentyx/Skyrizi), and CGRP migraine (Emgality). Taiwan Rx DTC restricted (藥事法); HOWEVER diabetes is a category where unbranded disease-awareness can run at high consumer reach (T2D prevalence ~11% in TW adults — 2.3M+ patients). Obesity Rx (Zepbound) — if TFDA approves — would be a category-defining DTC moment globally Lilly has pushed limits in US DTC (Zepbound consumer ads); Taiwan TFDA would restrict more but unbranded weight-management awareness is feasible. Estimated NT$200-400M ad spend currently, with significant UPSIDE if Mounjaro/Zepbound consumer-awareness waves accelerate.

Signal timeline · last 90 days
0 of 0 shown
No signals captured in the last 90 days. Account is monitored daily — next ingest will pick up MOPS filings + RSS hits automatically.
The arithmetic of 95
score breakdown
AOR 7y with WPP (creative — VML, Ogilvy Health, Hogarth production); media mixed (Mediahub/IPG historical)aor_anniversary_5y+50
Intel depth (6 wedges · M&A, recent)research_depth+47
Total · capped 9595
30-day signal trajectory
0 signals · spend N/A
Intel wedges
6/8
6 of 8 wedges corroborated. Research confidence: medium.
Open playbook →
Recommended posture
Pitch now.
Global creative consolidation to WPP (2019) — Lilly named WPP its strategic creative + production partner globally. CORE WPP RELATIONSHIP. Renewed since.